Cite
HARVARD Citation
Yubero, A. et al. (n.d.). 2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO. International journal of gynecological cancer. p. A238. [Online].